SMILES string
Fc1c(cc(cc1)F)N([S](=O)(=O)c3ccc(cc3)Cl)[C@H](C)c2c(cc(cc2)F)CCCC(=O)O
InChI
1S/C24H21ClF3NO4S/c1-15(21-11-7-18(26)13-16(21)3-2-4-24(30)31)29(23-14-19(27)8-12-22(23)28)34(32,33)20-9-5-17(25)6-10-20/h5-15H,2-4H2,1H3,(H,30,31)/t15-/m1/s1
InChI key
IZAOBRWCUGOKNH-OAHLLOKOSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: ≥20 mg/mL
storage temp.
−20°C
Quality Level
Application
BMS-299897 has been used as an γ-secretase inhibitor to stop high glucose (HG) mediated amyloid β-peptide (Aβ) secretion.
Biochem/physiol Actions
BMS-299897 is a gamma-secretase inhibitor
BMS-299897 is a potent inhibitor of γ-secretase. The comound is 15-fold more selective for inhibiting the cleavage of β-amyloid precursor protein over Notch cleavage (IC50s 7.1 and 105.9, respectively). In vivo, BMS-299897 blocks the formation of Aβ40 and Aβ42 in the brain and CSF without affecting maturation of CD8+ T cells or intestinal goblet cells, suggesting Notch signalling was not significantly inhibited.
BMS-299897 may be used as a therapeutic for Alzheimer′s disease.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
A-Ching Chao et al.
CNS neuroscience & therapeutics, 22(4), 291-297 (2016-02-05)
Amyloid beta-peptide (Aβ), the main component of senile plaques in the Alzheimer's disease (AD) brains, is generated from sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretase. Hyperglycemia in diabetes may compromise barrier integrity in endothelial cells (ECs).
Donglu Zhang et al.
Current drug metabolism, 7(8), 883-896 (2006-12-16)
BMS-299897 is a gamma-secretase inhibitor that has the potential for treatment of Alzheimer's disease. The metabolism of [(14)C]BMS-299897 was investigated in human liver microsomes, in rat, dog, monkey and human hepatocytes and in bile duct cannulated rats. Seven metabolites (M1-M7)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持